Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid progress made in their cell therapy business which is focused on driving adoption of its non-viral cell engineering technology Flow Electroporation across its ExPERT instrument platform.
MaxCyte Inc 'demonstrating outstanding progress' as first half revenues climb 30%
Quick facts: MaxCyte Inc
Price: 332 GBX
Market Cap: £256.17 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE